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Abstract 
It has been known for many years that substantial weight loss, achieved by bariatric surgery or non-
surgical means can mean normalise glucose tolerance.  Recent RCT evidence indicates that >15 kg 
weight loss is necessary, to this and it may lead to near normalisation (doubling) of life expectancy.  
Less than 5% of patients achieve this through even the best, evidence-based medical weight 
management programme (Counterweight www.counterweight.org ). 
 
A weight loss of >15 kg is easily achievable by 8 weeks VLED/LELD in compliant patients, with little 
difference between 400-800 kcal/day, but weight maintenance after VLED has until recently been so 
poor that VLEDs are not, at present, recommended in clinical guidelines.  However, mean weight loss 
close to >15 kg can be maintained 18-24 months using a variety of maintenance strategies.  These 
include a structured reintroduction of foods linked to an education programme with behavioural 
strategies, intermittent VLED use and prescribable anti-obesity drugs (dexfenfluramine, orlistat, 
sibutramine).  Most of these studies have been in non-diabetic subjects. 
 
A new “curative” paradigm in T2DM management, aiming to normalise glucose tolerance and health 
risks by achieving and maintaining >15 kg loss, as soon as possible after diagnosis, should  be highly 
acceptable to patients, generating many additional QALYs. It is likely to be highly cost-effective by 
avoiding the current recommended, mainly palliative, model, using polypharmacy which provides an 
overall risk reduction of only 5-10%.. 
 
Clinical trials are on-going to establish the feasibility of delivering formula (LELD) and a maintenance 
programme to large numbers of patients within routine primary care.  There is urgent need, to run 
similar studies in diabetic patients.  New approaches to long-term (lifelong) maintenance of weight 
loss and a non-diabetic state may include anti-obesity drugs.   
286 words 
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Introduction 
Over the past 100 years paradigms for the management of Type 2 Diabetes Mellitus (T2DM) have 
cautiously edged from purely symptom-relief (glucose lowering) firstly towards microvascular risk 
reduction (glucose normalising, BP lowering) and most recently towards a focus on macrovascular 
risk reduction (combined glucose, BP and lipid lowering, anti-thrombolic treatments).  This progress 
based on clearer recognition of the clinical impact of diabetes, has unfortunately led to a situation 
where most T2DM patients are soon prescribed, according to current evidence-based guidelines, 6-8 
different drugs every day for life.  Their combined effect has been estimated to reduce CVD risks by 
only about 5-10%.  Many patients already have or soon develop onset cardiovascular disease, 
requiring further drug treatment e.g. anti-anginal, as well as drugs for other obesity-induced problems 
(arthritis, depression, etc).  Thus many T2DM patients are prescribed 8-12 drugs, but the underlying 
disease process continues. The risk of T2DM is exceedingly low at BMI 21-22, but rises to 5 times 
this level with BMI 25, about 30 times this level with BMI 30 and Relative Risk rises to almost 100 with 
BMI above 35.1  The lifetime risk of T2DM is greater for those who become obese at a young age, but 
the effect is seen into old age.  With BMI >35, the remaining average lifetime risk of T2DM is 79% at 
18, 60% at age 45, and 35% at age 65.2  This makes T2DM the disease most strongly linked with 
weight gain and obesity, and from first principles the argument is unassailable that weight 
management should be the primary avenue of treatment.  If weight loss and maintenance is not 
possible, then it remains valuable to add more palliative drug treatments. 
 
Although the development of T2DM depends on weight gain and obesity, and all its pathogenic 
consequences are prevented or reversed by weight loss, weight management receives little more 
than lip-service in most clinical guidelines and diabetes care services.  For example, SIGN diabetes3 
offers no target, and no recommended weight management approach, but refers to the SIGN Obesity 
Guideline (2010)4 which does not contain any guidance for weight management in diabetes.  The IDF 
global guideline offers no target.5,6  It is still considered difficult, or a waste of time to provide effective 
weight management even though modest, achievable weight loss (5-10 kg) has been shown to bring 
major clinical benefits.  Many patients with T2DM never see a dietitian.7  Patients want to lose weight, 
but find insufficient value from the effort required for them to sustain this degree of loss, and seek 
greater loss.8,9 
 
In principle, a VLED/LELD supplying only 400-800 kcal/day will induce an energy deficit of 2000-3000 
kcal/day for any severely obese patient – and more if the patient is extremely obese, or is physically 
active.  Any patient who is fully compliant with VLED/LELD will thus lose 2-3 kg/week, even allowing 
for the compensatory temporary fall in metabolic rate.10,11  There is usually more rapid loss in the first 
week, through glycogen depletion and water loss.  This degree of energy defect and obligatory weight 
loss is very similar to that in the early months after bariatric surgery.  The only difference is that 
surgery usually provides a physical obstacle to excessively increased intake and regain. 
 
Clinical Obesity – Draft 5 – 03.09.10 
 4 
Bariatric surgery has been promoted as a treatment for T2DM, by bariatric surgeons and their 
patients, for many years.  As long ago as 1992 Pories and colleagues published their data on 288 
patients with diabetes or glucose tolerance, of whom 258 reverted to normal glucose tolerance, with 
the conclusion “Diabetes is a surgical disease”.12  More recently a colossal systematic review and 
meta-analysis concluded that some 75% would be restored to a non-diabetic state by bariatric 
surgery.13  Suspicion about the uncontrolled nature of these data precluded this evidence being 
included in guidelines for diabetes care.  However, the results were essentially identical to those 
published from the Swedish Obese Subjects (SOS) which did have a non-intervention control group14, 
and any doubt has been erased by a well-conducted RCT which again showed 73% of T2DM 
(diagnosed less than 2 years) reverted to normal glucose tolerance at 2 years following laparoscopic 
banding surgery.15   The claim of surgeons that this is a “cure” may be true for many, although it is 
possible that metabolism will slip back to a diabetic state at some future stage. However, normal 
glucose tolerance means freedom from stigmatisation and insurance penalties, freedom from 
complications of diabetes, and freedom from the need for lifelong expensive and intrusive palliative 
treatments. 
 
A new target – 15 kg loss 
A key observation from the RCT of bariatric surgery for obese patients with T2DM, is that resolution of 
diabetes to normal glucose tolerance, at 2 years, occurred almost exclusively in those patients who 
lost and maintained >15 kg below baseline (in both surgical and medical control groups).15  Those 
who maintained less than 15 kg loss at 2 years failed to achieve normal glucose tolerance [figure 
1].15  The results should not be extrapolated to all T2DM patients.  They were a relatively young and 
otherwise healthy group.  Importantly, they were treated within 2 years of diagnosis of T2DM – before 
serious depletion of beta-cell reserves.  
 
This treatment threshold of 15 kg loss appears to be a new clinical reality for patients with severe and 
complicated obesity, as the amount needed to reverse the most intractable complication of obesity.  
There are few hazards to patients in losing >15 kg, and many other benefits accrue, so this seems a 
reasonable target for weight management.  It is supported by other non-surgical weight loss data. 
Wing et al 1987; Klein 2001 showed improved diabetic control with weight loss and weight loss of 
>=15 kg resulted in normalisation of both glucose and insulin [Figure 2].16,17  VLED leads to a very 
rapid improvement in glycaemia, with normalisation as soon as 2 weeks shown in a meta-analysis by 
Anderson et al  2003.18  Intentional weight loss has been shown in several studies to be associated 
with increased survival in patients with T2DM.19,20   
 
Life expectancy is reduced 5-20 years by T2DM, through increased CHD x 2-3, cancers, and 
infections and obesity aggravates all the risk factors so life expectancy is further reduced.  At age 64, 
the mean life expectancy in an unselected clinic population with T2DM is only 6-8 years, which 
compares with 12-15 years in non-diabetic people of the same age locally.19,21  The clinical audit of 
Lean et al 199019 had particular statistical strength in having followed up from diagnosis to death a 
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cohort defined by year of death.  The numbers of patients who lost over 12 kg under the clinic dietitian 
was too small to make confident predictions, but an extrapolation of the study results suggested that 
survival would be increased by 8 years with 15 kg loss – restoring the life expectancy of those 
overweight T2DM patients close to the level expected for non-diabetic patients of the same age 
(mean age 64 at diagnosis) [Figure 3]. 
 
In principle, it is therefore reasonable to expect that for most patients weight loss >15 kg achieved by 
any means, would restore patients with recent onset of T2DM to normal glucose tolerance, and avoid 
or at least delay appallingly all the clinical consequences of diabetes.  It is already well established 
that weight loss has a more dramatic effect than any oral hypoglycaemic on glycaemic drugs and can 
normalise the dyslipidaemia of T2DM18 and lowers the blood pressure of hypertensive patients more 
than any hypertensive drug.  These metabolic effects of weight loss are all sustained for at least 10 
years, if weight gain is provided, with the possible exception of the hypotensive effect.22,14  
 
On these grounds, the evidence is very persuasive that effective and sustained weight loss at 
diagnosis with a target >15 kg, should be recommended as the top priority in managing T2DM.  The 
timing of treatment may be important, as a failure to lose weight leaves the underlying disease 
process, which progresses to beta-cell loss such that restoration of normal glucose tolerance will 
become less likely.  From the patients’ perspective, restoration of normal glucose tolerance which 
would also be accepted as a “cure” for insurance purposes, should be very attractive.  The alternative 
management for T2DM, as currently recommended by guidelines, is essentially palliative.  Patients 
with T2DM are given only token or very general advice for weight loss23,3 and are frequently 
prescribed 6-8 “diabetes-related” drugs to take daily – or more if they are hypertensive.  These drugs 
are based on evidence that blood glucose lowering has a modest effect in delaying macrovascular 
complications of diabetes (and a cocktail of lipid-lowering, anti-thrombotic and anti-hypertensive drugs 
reduces the risk of CHD).  The net effect of this polpharmacy is to reduce the overall CHD risk of 
T2DM patients by just 5-10%.24,25  These drugs are prescribed for life, and can cause side effects.  
Obese diabetic patients can expect also to need other drugs for conditions caused or aggravated by 
obesity, such as H2-blockers, analgesics for arthritis or back pain, diuretics, anti-anginals and anti-
depressants.  It is thus not uncommon for obese T2DM patients to be prescribed 8-12 drugs and 
some more.  Patients commonly do not take this medication.26  Most, including all the medication for 
diabetes could become unnecessary with sufficient weight loss.   
 
There are multiple clinical benefits affecting many body systems from weight loss [Figure 4].27   
These benefits will accrue for obese T2DM patients just as for anyone else, and outweigh the fairly 
small risk of clinical hazards of major weight loss, such as symptomatic gall stones which develop in 
about 5-10%.28  
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Combining treatments for weight management for T2DM 
Clinical guidelines have identified three aims of weight management which need to be addressed 
separately: initial weight loss, long-term maintenance and risk-reduction.  Conventional weight 
management with a 5-10 kg target can be effective, but should always use an evidence-based, 
structured, approach following clinical guidelines4,29 based mainly on modifying food choices and 
incorporating physical activity when that becomes possible, with options for anti-obesity drugs where 
appropriate.  This approach has been fully evaluated by the Counterweight Programme.30  It is highly 
cost-effective, on an ITT basis, indeed cost-saving through long-term cost avoidance.31  However, the 
target of 5-10 kg loss at 1-2 years was achieved by only 30% of attenders, or 1 in 6 of all those who 
enter the programme.  That is the reality of what can be achieved by ‘all-comers’ in routine primary 
care using the best available methods.  Patients with T2DM tend to do less well, for a variety of 
reasons: metabolic rates tend to fall with improved diabetic control, hypoglycaemic drugs often cause 
weight gain, and these patients have usually already tried their best with diet and lifestyle. 
 
If the real target for obese patients with T2DM is a maintained 15 kg weight loss, conventional diet 
and exercise programmes will not suffice.  Only 2% of patients achieved this in the Counterweight 
audit.  Using anti-obesity drugs together with a good diet and exercise programme has been shown to 
increase success rates in clinical trials, but still only about 5-10% of patients will maintain 15 kg loss 
with orlistat32 or sibutramine33 [ref].  The main benefit for obese patients from anti-obesity drugs is 
from improved long-term weight maintenance, not just for weight loss.  Patients find weight 
maintenance in our obesogenic environment more difficult than achieving weight loss.  It has been 
difficult to assess the expected clinical impact of these drugs in routine clinical practice, because the 
published RCT results include substantial numbers of patients who do not respond to the drug, and 
who should be withdrawn from treatment at an early stage.  Anti-obesity drugs do not benefit all 
patients equally, and should not be expected to. 
 
The results of trials with all recently studied anti-obesity drugs show consistently that a mean weight 
loss of around 4-7 kg is maintained at 1-2 years34 [Figure 5] but studies which have used other 
methods to gain greater initial weight loss have demonstrated weight maintenance at a mean of about 
10-12 kg below the baseline weight with sibutramine.35,36  Similarly with orlistat a mean weight loss 
10-15 kg is seen for compliant, responding patients who achieve >4 kg loss at 3 months and then 
continue on treatment.32  A significant proportion of these patients managed to maintain >15 kg loss at 
1-2 years.  Results in obese patients with T2DM consistently show poorer weight loss.  Most recently 
the data for liraglutide, has shown a mean weight loss of about 8 kg at 20 weeks37 with further 
subsequent loss to 10-11 kg below baseline, maintained at 12 months in a RCT when it is given 
together with a good diet and exercise programme to non-diabetic patients with obesity.38  Liraglutide 
is licenced for diabetes treatment, and alone leads to modest weight loss maintained at about 3 kg 
below control groups39 and does generate weight loss, but has not been studied formally together with 
a good diet and exercise weight-loss programme for obese T2DM patients, or in a realistic, routine 
clinic setting. 
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It has been shown many times that VLEDs can generate much more weight loss than conventional 
food-based diets, but weight regain has been a huge problem, preventing the recommendation of 
VLED in evidence-based guidelines.  Meta-analysis of 80 non-surgical trials with 1-year follow-up 
found a mean initial weight loss of about 18 kg, which is approaching that achieved in some bariatric 
surgery series40 e.g. mean 21 kg loss at 2 years following laparoscopic banding.15  However, weight 
regained rapidly to around 11 kg at 12 months and 8 kg at 2 year.40  This is in fact somewhat better 
than can be achieved by food-based diets and probably deserves re-evaluation by guideline-writers, 
but the regain is frustrating for both patients and treatment providers, and the numbers able to 
maintain weight loss >15 kg is still very small. 
 
Given the proven value of anti-obesity medications for improving long-term weight maintenance, it is 
surprising that more studies have not combined VLED (for the weight loss phase) with full medical 
supporting treatment, including drugs where appropriate, for maintenance.  The marketing, and 
indeed the regulatory processes for anti-obesity treatments, have almost exclusively focussed on the 
weight loss, to the disadvantage of patients whose greatest medical need is to improve weight 
maintenance. 
 
There are several ways to enhance weight maintenance.  The Counterweight studies demonstrated 
almost complete maintenance between 1 and 2 years, and in common with many other studies, 
showed that frequency of follow-up attendance and contact with healthcare professionals with some 
behavioural skills had the most important effect30.  A structured approach to the maintenance period is 
clearly important and has been neglected in the past.  A recent Danish study has used a stepped food 
reintroduction programme to achieve good results.41  This type of approach has few costs and 
engages and empowers patients in the area they find most problematic.  
 
Several trials have been published over the years, and all have shown substantial benefit in terms of 
long-term weight maintenance when a licenced anti-obesity drug was added to the effect of a VLEDb.  
Using dexfenfluramine (now no longer available) a mean weight loss of about 18 kg with VLED was 
increased to near 28 kg at 34 weeks.42 [Figure 6a]  A similar study by Andersen, Astrup, Quaade 
however showed no benefit for dexfenfluramine at 12 months, so not all maintenance programmes 
are equally effective.43  Using sibutramine, Apfelbaum et al showed substantial additional effect 
following initial weight loss after VLED, with a maintained mean loss of 14 kg.  Almost half these 
patients thus maintained >15 kg loss.44 [Figure 6b]  Importantly these clinic based results have been 
replicate in a more realistic primary care setting, in Holland, again showing a mean loss of 14 kg at 12 
months, with sibutramine after VLED and further maintenance to 18 months.45 [Figure 6c]  A recent 
study using orlistat has produced very similar results, with weight loss maintained on a low-fat diet at 
about 14 kg below baseline at 12 months, 11 kg at 24 months and 9 kg at 36 months.  A placebo-
treated control group did less well, but still lost one 7 kg at 3 years.  Importantly the programme was 
very well accepted with 200 out of 309 completing 3 years.46 [Figure 6d]  A feasibility study is now 
well advanced in UK primary care, using 810 LCLD with orlistat to complement the excellent weight 
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maintenance diet and exercise methods developed by the Counterweight Programme.  Early results 
show high levels of acceptability to both patients and primary care teams, and excellent early weight 
loss.  There is a clear need to extend this work to T2DM patients. 
 
Conclusions 
The evidence reviewed here seems reasonably secure that the impressive short term weight losses 
achieved with VLED can be maintained quite well using a combination of behavioural methods and 
anti-obesity medications, such that approaching 50% of patients might be expected to lose >15 kg, 
the amount which appears to reverse a diagnosis of T2DM.  The results are not perfect and there is 
clearly scope for future research on improvements, particularly research based in realistic routine-
care settings, and specifically obese T2DM patients. 
 
For optimal weight loss there seems to be advantages in requiring patients to undertake a period on a 
purely synthetic liquid diet, including all essential micronutrients (LCLD).  Including specific foods, to 
try to improve acceptability, impairs weight loss.47  The recent studies of Riecke et al41 and the Taiwan 
study48 have shown very little difference in the weight loss effects of VLED (415 kcal/day) and a more 
liberal (810 kcal/day LCLD), so this seems the best approach to the weight loss phase under current 
evidence. 
 
For long term weight maintenance, behavioural methods are already effective, and can be improved 
and tailored to the needs of patients and to the skills of the supporting healthcare team.  Although the 
best, and possibly most cost-effective, results are likely to arise from bariatric surgery, adding anti-
obesity medication to behavioural approaches appears to generate results begin to challenge those 
from surgery.  Orlistat is effective and the GLP-1 agonists may prove even more so, with encouraging 
early results from liraglutide even without VLED.37,38  
 
Maintenance programmes without anti-obesity drugs or surgery such as that used in the look AHEAD 
trial suggest better outcomes with high amounts of exercise, compliance with protocol and use of 
formula food product.49  Preliminary evidence from a randomised controlled trial suggests that a highly 
motivated group (older people with knee osteoarthritis) given intense management and regular part 
substitution of regular food with formula food product during maintenance can maintain on average 
more than 10kg weight loss for one year with nearly half the patients maintaining major symptom 
improvement.50 [Figure 7]  
 
Waiting for the diagnosis of T2DM is not in patients’ best interests.  Providing more aggressive 
evidence-based weight management for all obese patients at an earlier stage may prove the most 
cost-effective strategy but T2DM will continue to be a major clinical problem.  If the evidence 
discussed here is accepted to adopt new, potentially curative, approach to manage T2DM in routine 
care, this will have huge benefits for patients above those from the current mainly palliative 
management, which has only minor impact on the disastrous prognosis of T2DM.  To allow this new 
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focus on effective weight management, targeting >15 kg loss, there will be training needs and 
decisions will need to be taken to divert some of the funds currently absorbed by current guideline-
driven management of T2DM and obesity and their complications.  These decisions will need secure 
evidence on acceptability effectiveness and cost-effectiveness. 
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Table 1 – What the Clinical Guidelines say 
 
SIGN 2010 – Obesity, No 115 
 
Key recommendation 2.2 
 
“in patients with BMI > 35 kg/m2 obesity-related comorbidities are likely to be present therefore weight 
loss interventions should be targeted to improving these comorbidities; in many individuals a greater 
than 15-20% weight loss (will always be over 10 kg) will be required to obtain a sustained 
improvement in comorbidity” 
 
 
 
 
Table 2 – Palliative polypharmacy for type 2 diabetes based on NICE/SIGN evidence-based 
guidelines  
 
 
Metformin 
+/- Insulin/SU/glitazone/gliptin/GLP-1 agonist 
Statin 
ACE inhibitor 
+ calcium channel inhibitor  
Beta-blocker 
Furosemide 
Aspirin +/- omeprazole 
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FIGURE 1 -  Percentage of Weight Loss Achieved Over the 2-Year Study Period (n = 60) and 
Individual Weight Measures at Baseline and at 2 Years  
Remission indicates those achieving remission of type 2 diabetes (see "Methods") at 2 years. 
Data markers with error bars indicate mean (SD).  [Dixon et al 2008] 
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Figure 2 – Weight change and glycaemic control at 12 months in patients with T2DM [Adapted 
from Wing et al, Klein S 2001] 
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Figure 3 -  Modest intentional weight loss increases life expectancy for overweight T2DM [Lean 
et al 1990] 
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Figure 4 – Multiple clinical benefits from weight loss 4y after laparoscopic adjustable gastric 
banding.  [Frigg et al, 2004] 
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Figure 5 – Proportion of study participants achieving 5-10% weight loss in one year, according 
to drug taken (data from combined datasets of 1 year phase 3 trials of three obesity drugs 
including rimonabant (adapted from Finer N) [Lean & Finer, 2006] 
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Figure 6a – 330 kcal/d VLCD followed by dexfenfluramine [Finer, 1992] 
 
 
 
 
 
 
 
 
 
 
Figure 6b – Weight loss after VLED – Sibutramine [Apfelbaum et al, 1999] 
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Figure 6c – VLED with sibutramine for long-term maintenance in a GP setting [Mathus-Vliegen et 
al, 2005] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6d – Body weight changes [Richelsen et al, 2007] 
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Figure 7 – Difference between 415 kcal VLED or 810 kcal LED [Christensen et al, 2010] 
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